SCHEDULE: Satterfield Discloses 9.9% Stake in BioCardia

Thomas A. Satterfield, Jr. has amended his Schedule 13G filing to report a beneficial ownership of 9.9% in BioCardia, Inc., primarily through direct holdings and exercisable warrants, subject to ownership limitations.

Summary

• Thomas A. Satterfield, Jr. has filed an amendment to Schedule 13G, reporting beneficial ownership of 1,539,134 shares of BioCardia, Inc. common stock.
• This represents approximately 9.9% of the outstanding common stock as of August 11, 2026.
• The reported ownership includes 1,271,165 directly owned shares and 267,969 shares issuable upon exercise of warrants.
• A 'blocker provision' limits the exercise of warrants to prevent beneficial ownership exceeding 9.99% of the outstanding common stock.
• The filing details various entities through which Mr. Satterfield holds shares, including Tomsat Investment & Trading Co., Inc., A.G. Family L.P., and Caldwell Mill Opportunity Fund, LLC.
• Mr. Satterfield also holds limited power of attorney for voting and disposition of shares held by Rebecca A. Satterfield.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but capped ownership stake due to blocker provisions, indicating a substantial investor presence without immediate control implications.

Positives

• Significant beneficial ownership reported by Thomas A. Satterfield, Jr., indicating substantial investor interest.
• The ownership stake of 9.9% is close to the 9.99% blocker limit, suggesting a strong conviction in the company.
• Detailed breakdown of holdings across different entities provides transparency.

Negatives

• The 'blocker provision' on warrants caps the potential ownership and control Mr. Satterfield can exert, limiting upside from warrant exercise.
• The filing indicates that if there were no blocker provision, Mr. Satterfield could potentially own 14.29% of the company, highlighting a missed opportunity due to the cap.

Risks

• The blocker provision limits the ability to increase ownership beyond 9.99%, potentially hindering future strategic moves or influence.
• Reliance on warrants, which are subject to exercise limitations, introduces uncertainty regarding full ownership realization.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of current ownership status.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders to disclose holdings exceeding 5% of a company's stock. The presence of a blocker provision is a strategic tool often employed by warrant holders to manage ownership levels and comply with regulatory thresholds or investment mandates.

Related Party Transactions

• Shares held by Tomsat Investment & Trading Co., Inc. (wholly owned by Mr. Satterfield).
• Shares held by A.G. Family L.P. (managed by a general partner controlled by Mr. Satterfield).
• Shares held by Caldwell Mill Opportunity Fund, LLC (Mr. Satterfield owns 50% and serves as Chief Investment Manager).
• Limited power of attorney for voting and disposition of shares held by Rebecca A. Satterfield.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant, albeit capped, stake by a key investor, which could influence market perception and trading activity.
• Management/Board: The ownership level may warrant attention from the board regarding investor relations and potential influence on corporate strategy.

Next Steps

• Monitor future filings from Thomas A. Satterfield, Jr. for any changes in beneficial ownership.
• Observe BioCardia, Inc.'s strategic developments and how they might be influenced by significant shareholders.

Key Dates

Keywords

BioCardia, Schedule 13G, Beneficial Ownership, Thomas A. Satterfield, Jr., Warrants, Blocker Provision, Investment